My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.050 -0.480 (-31.37%)
Streaming Delayed Price Updated: 3:15 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
Via CannabisNewsWire
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
- DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
Via CannabisNewsWire
CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
Via CannabisNewsWire
BTV Highlights Promising Investment Opportunities
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - On Sat. Sept 25th at 5pm EST broadcast on FOX Business... 
Via Newsfile
Topics Artificial Intelligence
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
Via CannabisNewsWire
Lexaria Takes Another Step Towards NDA Filing for DehydraTECH- CBD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins IND-Enabling Program for DehydraTECH-CBD for Hypertension
Via CannabisNewsWire
Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension
Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH... 
Via Benzinga
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in... 
Via Newsfile
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented... 
Via Benzinga
Why Lexaria Bioscience Shares Are Trading Higher Today
Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential... 
Via Benzinga
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%
Via CannabisNewsWire
Topics Animal Testing Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery
Via CannabisNewsWire
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.